XOMA Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
XOMA Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$25.28 |
52 Week High | US$27.36 |
52 Week Low | US$13.48 |
Beta | 0.85 |
1 Month Change | 2.31% |
3 Month Change | -3.95% |
1 Year Change | 47.84% |
3 Year Change | -16.87% |
5 Year Change | 52.01% |
Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?
Apr 03Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?
Sep 01Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates
Aug 11XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M
Aug 04Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically
May 08Xoma Gets The Spotlight
Sep 02Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade
Aug 20We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right
May 13Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?
May 11XOMA EPS misses by $0.55, misses on revenue
May 06XOMA gets milestone payment from Janssen Biotech
May 03XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality
Mar 17Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be
Mar 16Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?
Mar 09Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?
Feb 02XOMA: A Royalty Aggregator To Watch
Jan 04XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?
Dec 29XOMA prices $22M offering of series A cumulative perpetual preferred stock
Dec 11Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?
Dec 01XOMA earns $2M milestone payment from Takeda
Nov 16XOMA receives first royalty payment from Agenus
Nov 11Shareholder Returns
XOMA | US Biotechs | US Market | |
---|---|---|---|
7D | 5.1% | 0.02% | 1.2% |
1Y | 47.8% | 6.7% | 20.6% |
Return vs Industry: XOMA exceeded the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: XOMA exceeded the US Market which returned 20.5% over the past year.
Price Volatility
XOMA volatility | |
---|---|
XOMA Average Weekly Movement | 6.5% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: XOMA has not had significant price volatility in the past 3 months.
Volatility Over Time: XOMA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1981 | 13 | Owen Hughes | www.xoma.com |
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Corporation Fundamentals Summary
XOMA fundamental statistics | |
---|---|
Market cap | US$310.75m |
Earnings (TTM) | -US$45.08m |
Revenue (TTM) | US$5.81m |
50.6x
P/S Ratio-6.5x
P/E RatioIs XOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XOMA income statement (TTM) | |
---|---|
Revenue | US$5.81m |
Cost of Revenue | US$122.00k |
Gross Profit | US$5.69m |
Other Expenses | US$50.77m |
Earnings | -US$45.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.87 |
Gross Margin | 97.90% |
Net Profit Margin | -775.86% |
Debt/Equity Ratio | 146.6% |
How did XOMA perform over the long term?
See historical performance and comparison